Imagin Medical Inc.

Imagin Medical is a surgical imaging company developing advanced optic and light sensor technology to dramatically improve physicians' ability to visualize cancer during minimally invasive surgery.
Imagin Medical announced on-going research feedback on its i/Blue™ Imaging System which allows simultaneous viewing of white and blue light images during bladder cancer resection procedures.
read more >
The company continues to advance its device toward commercialization.
read more >
The disruptive technology is 'poised to deliver significant advancement in bladder cancer detection.'
read more >
In doing so, it gets one step closer to market approval from U.S. regulators.
read more >
The company aims to conduct pilot production testing in Q1/20.
read more >

Experts Following This Company

Knox Henderson
Clive Maund –

The information provided above is from analysts, newsletters, the company and other contributors.

Imagin Medical Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights
Bringing new standard of care to bladder cancer through surgical imaging
Early stage opportunity - $4B market opportunity - most expensive cancer to treat due to recurrence
Poised for strategic growth with strong management
catalyst Calendar
Functional Unit
Verified Unit
FDA Approval